GPT and Hyperglycemia: The most common grade 3–4 (G3–4) adverse events in the buparlisib group versus the placebo group were increased alanine aminotransferase (146 (25%) of 573 patients vs. six (1%) of 570), increased aspartate aminotransferase (103 (18%) vs. 16 (3%)), hyperglycemia (88 (15%) vs. one (<1%)), and rash (45 (8%) vs. none).